Deferred Income Tax Expense (Benefit) of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2022 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Mar 2022 to 30 Jun 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Deferred Income Tax Expense (Benefit) for the quarter ending 30 Jun 2025 was $4,884,535, a 26725% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Deferred Income Tax Expense (Benefit) for 2024 was $3,795,147.
  • ELITE PHARMACEUTICALS INC /NV/ annual Deferred Income Tax Expense (Benefit) for 2023 was $19,989,074.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)
Deferred Income Tax Expense (Benefit), Annual (USD)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $4,884,535 +$4,866,326 +26725% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q2 2024 $18,209 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2026 Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,795,147 +$23,784,221 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025 2025 FY
2023 $19,989,074 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025 2025 FY
2021 $2,171,821 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.